Ardeschir Ghofrani

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3367351/publications.pdf

Version: 2024-02-01

511 papers	54,821 citations	2322 98 h-index	1505 219 g-index
580 all docs	580 docs citations	580 times ranked	25311 citing authors

#	Article	IF	Citations
1	Genetic deletion of p66shc and/or cyclophilin D results in decreased pulmonary vascular tone. Cardiovascular Research, 2022, 118, 305-315.	3.8	8
2	A novel non-invasive and echocardiography-derived method for quantification of right ventricular pressureâ€“volume loops. European Heart Journal Cardiovascular Imaging, 2022, 23, 498-507.	1.2	22
3	Exercise hemodynamics in heart failure patients with preserved and mid-range ejection fraction: key role of the right heart. Clinical Research in Cardiology, 2022, 111, 393-405.	3.3	5
4	Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. European Respiratory Journal, 2022, 59, 2102024.	6.7	57
5	Risk assessment in pulmonary hypertension based on routinely measured laboratory parameters. Journal of Heart and Lung Transplantation, 2022, 41, 400-410.	0.6	12
6	COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. European Respiratory Journal, 2022, 60, 2102311.	6.7	124
7	Targeting peptidyl-prolyl isomerase 1 in experimental pulmonary arterial hypertension. European Respiratory Journal, 2022, 60, 2101698.	6.7	5
8	Childhood Trauma in Patients With PAHâ€”Prevalence, Impact on QoL, and Mental Healthâ€”A Preliminary Report. Frontiers in Psychiatry, 2022, 13, 812862.	2.6	0
9	Refined risk stratification in pulmonary arterial hypertension and timing of lung transplantation. European Respiratory Journal, 2022, 60, 2103087.	6.7	7
10	Childhood Maltreatment, Mental Well-Being, and Healthy Lifestyle in Patients With Chronic Thromboembolic Pulmonary Hypertension. Frontiers in Psychiatry, 2022, 13, 821468.	2.6	1
11	Relevance of Cor Pulmonale in COPD With and Without Pulmonary Hypertension: A Retrospective Cohort Study. Frontiers in Cardiovascular Medicine, 2022, 9, 826369.	2.4	8
12	Prevalence of Mental Disorders in Patients With Chronic Thromboembolic Pulmonary Hypertension. Frontiers in Psychiatry, 2022, 13, 821466.	2.6	7
13	Unmasking right ventricular-arterial uncoupling during fluid challenge in pulmonary hypertension. Journal of Heart and Lung Transplantation, 2022, 41, 345-355.	0.6	12
14	SPARC, a Novel Regulator of Vascular Cell Function in Pulmonary Hypertension. Circulation, 2022, 145, 916-933.	1.6	21
15	Inhaled Iloprost Improves Right Ventricular Loadâ€“Independent Contractility in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 111-114.	5.6	10
16	Metacognitions in Patients With Frequent Mental Disorders After Diagnosis of Pulmonary Arterial Hypertension. Frontiers in Psychiatry, 2022, 13, 812812.	2.6	2
17	Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres. ESC Heart Failure, 2022, 9, 2873-2885.	3.1	5
18	Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. Lancet Respiratory Medicine,the, 2022, 10, 937-948.	10.7	57

#	Article	IF	Citations
19	Mitochondrial Respiration in Peripheral Blood Mononuclear Cells Negatively Correlates with Disease Severity in Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2022, 11, 4132.	2.4	7
20	Amelioration of elastaseâ€induced lung emphysema and reversal of pulmonary hypertension by pharmacological iNOS inhibition in mice. British Journal of Pharmacology, 2021, 178, 152-171.	5.4	17
21	Current and future treatments of pulmonary arterial hypertension. British Journal of Pharmacology, 2021, 178, 6-30.	5.4	104
22	CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension. European Respiratory Journal, 2021, 57, 1901192.	6.7	15
23	Congestive nephropathy: a neglected entity? Proposal for diagnostic criteria and future perspectives. ESC Heart Failure, 2021, 8, 183-203.	3.1	82
24	Right heart failure in pulmonary hypertension: Diagnosis and new perspectives on vascular and direct right ventricular treatment. British Journal of Pharmacology, 2021, 178, 90-107.	5.4	40
25	Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders. International Journal of Environmental Research and Public Health, 2021, 18, 1692.	2.6	43
26	Therapeutic Potential of Regorafenibâ€”A Multikinase Inhibitor in Pulmonary Hypertension. International Journal of Molecular Sciences, 2021, 22, 1502.	4.1	4
27	Reply to â€œRisk stratification in PH associated with interstitial lung disease: The Holy Grail?â€• Journal of Heart and Lung Transplantation, 2021, 40, 317.	0.6	0
28	Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension. EClinicalMedicine, 2021, 34, 100822.	7.1	22
29	Prevalence of Mental Disorders and Impact on Quality of Life in Patients With Pulmonary Arterial Hypertension. Frontiers in Psychiatry, 2021, 12, 667602.	2.6	30
30	Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism. Blood, 2021, 137, 2681-2693.	1.4	11
31	Right ventricular pressure-volume loop shape and systolic pressure change in pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 320, L715-L725.	2.9	21
32	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 573-584.	10.7	85
33	Impact of SARS-CoV-2-Pandemic on Mental Disorders and Quality of Life in Patients With Pulmonary Arterial Hypertension. Frontiers in Psychiatry, 2021, 12, 668647.	2.6	9
34	Metabolic Reprogramming in Congenital Cyanotic Heart Disease: Another Fight in Puberty?. Circulation, 2021, 143, 2273-2276.	1.6	2
35	PINK1-mediated Mitophagy Contributes to Pulmonary Vascular Remodeling in Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2021, 65, 226-228.	2.9	9
36	Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2. Communications Biology, 2021, 4, 1002.	4.4	3

#	Article	IF	Citations
37	Osteopontin and galectin-3 as biomarkers of maladaptive right ventricular remodelingÂin pulmonary hypertension. Biomarkers in Medicine, 2021, 15, 1021-1034.	1.4	6
38	Exercise Hemodynamic Profiling Is Associated With Outcome in Patients Undergoing Percutaneous Mitral Valve Repair. Circulation: Cardiovascular Interventions, 2021, 14, e010453.	3.9	3
39	Impairment of hypoxic pulmonary vasoconstriction in acute respiratory distress syndrome. European Respiratory Review, 2021, 30, 210059.	7.1	16
40	Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry. Cardiovascular Diagnosis and Therapy, 2021, 11, 1255-1268.	1.7	8
41	ERS statement on chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2021, 57, 2002828.	6.7	287
42	TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension. Pulmonary Circulation, 2021, 11, 1-7.	1.7	24
43	Impact of Pulmonary Arterial Hypertension on Employment, Work Productivity, and Quality of Life - Results of a Cross-Sectional Multi-Center Study. Frontiers in Psychiatry, 2021, 12, 781532.	2.6	5
44	Clinical Relevance of Right Atrial Functional Response to Treatment in Pulmonary Arterial Hypertension. Frontiers in Cardiovascular Medicine, 2021, 8, 775039.	2.4	3
45	Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH. Pulmonary Circulation, 2020, 10, 1-12.	1.7	6
46	Evaluation and Prognostic Relevance of Right Ventricularâ€“Arterial Coupling in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 116-119.	5.6	68
47	Association of right atrial conduit phase with right ventricular lusitropic function in pulmonary hypertension. International Journal of Cardiovascular Imaging, 2020, 36, 633-642.	1.5	16
48	Right ventricular function correlates of right atrial strain in pulmonary hypertension: a combined cardiac magnetic resonance and conductance catheter study. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H156-H164.	3.2	42
49	Advanced risk stratification of intermediate risk group in pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-5.	1.7	14
50	IRAG1 Deficient Mice Develop PKG1Î² Dependent Pulmonary Hypertension. Cells, 2020, 9, 2280.	4.1	7
51	Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats. Pulmonary Circulation, 2020, 10, 1-16.	1.7	9
52	Impact of SARSâ€CoVâ€2 pandemic on pulmonary hypertension outâ€patient clinics in Germany: a multiâ€centre study. Pulmonary Circulation, 2020, 10, 1-3.	1.7	15
53	Risk assessment in severe pulmonary hypertension due to interstitial lung disease. Journal of Heart and Lung Transplantation, 2020, 39, 1118-1125.	0.6	15
54	Genetic Deficiency and Pharmacological Stabilization of Mast Cells Ameliorate Pressure Overload-Induced Maladaptive Right Ventricular Remodeling in Mice. International Journal of Molecular Sciences, 2020, 21, 9099.	4.1	5

#	Article	IF	Citations
55	Physical Activity and Mental Health of Patients with Pulmonary Hypertension during the COVID-19 Pandemic. Journal of Clinical Medicine, 2020, 9, 4023.	2.4	14
56	Evaluation of pulmonary hypertension by right heart catheterisation: does timing matter?. European Respiratory Journal, 2020, 56, 1901892.	6.7	9
57	A comprehensive echocardiographic method for risk stratification in pulmonary arterial hypertension. European Respiratory Journal, 2020, 56, 2000513.	6.7	42
58	Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. Journal of Clinical Medicine, 2020, 9, 1456.	2.4	21
59	Sex Differences in Right Ventricularâ€“Pulmonary Arterial Coupling in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1042-1046.	5.6	48
60	Influence of gender in monocrotaline and chronic hypoxia induced pulmonary hypertension in obese rats and mice. Respiratory Research, 2020, 21, 136.	3.6	5
61	NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. Nature Metabolism, 2020, 2, 532-546.	11.9	23
62	Cytochrome P450 epoxygenaseâ€derived 5,6â€epoxyeicosatrienoic acid relaxes pulmonary arteries in normoxia but promotes sustained pulmonary vasoconstriction in hypoxia. Acta Physiologica, 2020, 230, e13521.	3.8	9
63	Yarsagumba is a Promising Therapeutic Option for Treatment of Pulmonary Hypertension due to the Potent Anti-Proliferative and Vasorelaxant Properties. Medicina (Lithuania), 2020, 56, 131.	2.0	5
64	Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-5.	1.7	6
65	FHL-1 is not involved in pressure overload-induced maladaptive right ventricular remodeling and dysfunction. Basic Research in Cardiology, 2020, 115, 17.	5.9	17
66	Right ventricular dyssynchrony: from load-independent right ventricular function to wall stress in severe pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 204589402092575.	1.7	5
67	SPARCL1 as a biomarker of maladaptive right ventricular remodelling in pulmonary hypertension. Biomarkers, 2020, 25, 290-295.	1.9	11
68	Bypassing mitochondrial complex III using alternative oxidase inhibits acute pulmonary oxygen sensing. Science Advances, 2020, 6, eaba0694.	10.3	39
69	Comparison of MRI and VQ-SPECT as a Screening Test for Patients With Suspected CTEPH: CHANGE-MRI Study Design and Rationale. Frontiers in Cardiovascular Medicine, 2020, 7, 51.	2.4	16
70	Reply to Bogaard et al.: Emphysema Isâ€”at the Mostâ€”Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1450-1452.	5.6	4
71	Enhanced circulating levels of CD3 cellsâ€derived extracellular vesicles in different forms of pulmonary hypertension. Pulmonary Circulation, 2019, 9, 1-4.	1.7	11
72	Acute response to rapid iloprost inhalation using the Breelibâ„¢ nebulizer in pulmonary arterial hypertension: the Breelibâ„¢ acute study. Pulmonary Circulation, 2019, 9, 1-3.	1.7	4

#	Article	IF	Citations
73	Is PKM2 Phosphorylation a Prerequisite for Oligomer Disassembly in Pulmonary Arterial Hypertension?. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1550-1554.	5.6	8
74	Pulmonary Vascular Pressure Response to Acute Cold Exposure in Kyrgyz Highlanders. High Altitude Medicine and Biology, 2019, 20, 375-382.	0.9	3
75	Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension. Circulation: Cardiovascular Imaging, 2019, 12, e009047.	2.6	222
76	Impaired right ventricular lusitropy is associated with ventilatory inefficiency in pulmonary arterial hypertension. European Respiratory Journal, 2019, 54, 1900342.	6.7	21
77	Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension. Respiratory Research, 2019, 20, 208.	3.6	16
78	Stem/Progenitor Cells in Cardiopulmonary Health, Disease, and Treatment. Stem Cells International, 2019, 2019, 1-4.	2.5	2
79	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005095.	2.2	8
80	Cardiopulmonary haemodynamics in portopulmonary hypertension. Lancet Respiratory Medicine,the, 2019, 7, 556-558.	10.7	3
81	Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2019, 38, 748-756.	0.6	29
82	Right ventricular function inÂpulmonary (arterial) hypertension. Herz, 2019, 44, 509-516.	1.1	17
83	Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension. Nature Communications, 2019, 10, 2204.	12.8	69
84	A simple echocardiographic estimate of right ventricular-arterial coupling to assess severity and outcome in pulmonary hypertension on chronic lung disease. European Respiratory Journal, 2019, 54, 1802435.	6.7	30
85	Severe Emphysema in the SU5416/Hypoxia Rat Model of Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 515-518.	5.6	20
86	Altered proteasome function in right ventricular hypertrophy. Cardiovascular Research, 2019, 116, 406-415.	3.8	9
87	Suppressor of Tumorigenicity 2 as a Biomarker in Pulmonary Arterial Hypertension and its Association with REVEAL Risk Score in Riociguat-Treated Patients in the RESPITE Study. Journal of Heart and Lung Transplantation, 2019, 38, S96.	0.6	0
88	Circulating Apoptotic Signals During Acute and Chronic Exposure to High Altitude in Kyrgyz Population. Frontiers in Physiology, 2019, 10, 54.	2.8	9
89	Protection against pressure overload-induced right heart failure by uncoupling protein 2 silencing. Cardiovascular Research, 2019, 115, 1217-1227.	3.8	16
90	Cardiac Magnetic Resonance Imaging-Based Right Ventricular Strain Analysis for Assessment of Coupling and Diastolic Function in Pulmonary Hypertension. JACC: Cardiovascular Imaging, 2019, 12, 2155-2164.	5.3	75

#	Article	IF	Citations
91	Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. Circulation, 2019, 139, 2440-2450.	1.6	67
92	Riociguat for treatment of pulmonary hypertension in COPD: a translational study. European Respiratory Journal, 2019, 53, 1802445.	6.7	25
93	Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1802004.	6.7	68
94	Reply to â€œa pediatric perspective on the TAPSE/PASP ratio in pulmonary arterial hypertensionâ€• International Journal of Cardiology, 2019, 278, 240-241.	1.7	1
95	Response by Tello et al to Letter Regarding Article, â€œValidation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertensionâ€• Circulation: Cardiovascular Imaging, 2019, 12, e010059.	2.6	13
96	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 227-238.	10.7	122
97	Evidence for the Fucoidan/P-Selectin Axis as a Therapeutic Target in Hypoxia-induced Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1407-1420.	5.6	39
98	Initial combination therapy with ambrisentanâ€¯+â€¯tadalafil on pulmonary arterial hypertensionâ€'related hospitalization in the AMBITION trial. Journal of Heart and Lung Transplantation, 2019, 38, 194-202.	0.6	19
99	Subcutaneous treprostinil: a new treatment for chronic thromboembolic pulmonary hypertension?. Lancet Respiratory Medicine,the, 2019, 7, 191-193.	10.7	1
100	Multibeat Right Ventricularâ€"Arterial Coupling during a Positive Acute Vasoreactivity Test. American Journal of Respiratory and Critical Care Medicine, 2019, 199, e41-e42.	5.6	8
101	Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. European Journal of Heart Failure, 2019, 21, 352-359.	7.1	40
102	Reserve of Right Ventricular-Arterial Coupling in the Setting of Chronic Overload. Circulation: Heart Failure, 2019, 12, e005512.	3.9	158
103	Treatment with lowâ€dose tacrolimus inhibits bleeding complications in a patient with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension. Pulmonary Circulation, 2019, 9, 1-3.	1.7	34
104	Chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801915.	6.7	607
105	Nitric Oxide Synthase 2 Induction Promotes Right Ventricular Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 346-356.	2.9	20
106	REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. Journal of Heart and Lung Transplantation, 2018, 37, 836-843.	0.6	29
107	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nature Communications, 2018, 9, 1416.	12.8	279
108	Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data. Scientific Reports, 2018, 8, 1300.	3.3	48

#	Article	IF	Citations
109	Impact of the mitochondria-targeted antioxidant MitoQ on hypoxia-induced pulmonary hypertension. European Respiratory Journal, 2018, 51, 1701024.	6.7	64
110	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. Journal of the American College of Cardiology, 2018, 71, 752-763.	2.8	82
111	Measures of subclinical cardiac dysfunction and increased filling pressures associate with pulmonary arterial pressure in the general population: results from the population-based Rotterdam Study. European Journal of Epidemiology, 2018, 33, 403-413.	5.7	3
112	Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. American Journal of Cardiovascular Drugs, 2018, 18, 37-47.	2.2	69
113	Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic disease. Pulmonary Circulation, 2018, 8, 1-6.	1.7	54
114	Beyond interleukin-6 in right ventricular function: Evidence for another biomarker. Journal of Heart and Lung Transplantation, 2018, 37, 674-675.	0.6	2
115	Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension. BMC Pulmonary Medicine, 2018, 18, 41.	2.0	46
116	Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENTâ€1/â€2 studies. Pulmonary Circulation, 2018, 8, 1-4.	1.7	26
117	Short-term venoarterial extracorporeal membrane oxygenation for massive endobronchial hemorrhage after pulmonary endarterectomy. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 643-649.	0.8	33
118	Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI 2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. Journal of Heart and Lung Transplantation, 2018, 37, 401-408.	0.6	15
119	ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 373-385.	5.6	78
120	REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. Journal of Heart and Lung Transplantation, 2018, 37, 513-519.	0.6	29
121	Response to: Comment on â€œEffect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Bandingâ€. BioMed Research International, 2018, 2018, 1-2.	1.9	0
122	Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study). Respiratory Research, 2018, 19, 258.	3.6	39
123	Evaluating Systolic and Diastolic Cardiac Function in Rodents Using Microscopic Computed Tomography. Circulation: Cardiovascular Imaging, 2018, 11, e007653.	2.6	10
124	EFFECT OF RIOCIGUAT ON RIGHT VENTRICULAR FUNCTION IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION. Chest, 2018, 154, 1065A-1066A.	0.8	0
125	Cologne consensus conference on pulmonary hypertension â€“ Update 2018. International Journal of Cardiology, 2018, 272, 1-3.	1.7	10
126	EFFECT OF RIOCIGUAT ON RIGHT VENTRICULAR FUNCTION IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. Chest, 2018, 154, 1062A-1064A.	0.8	0

#	Article	IF	Citations
127	Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. International Journal of Cardiology, 2018, 272, 37-45.	1.7	56
128	Exercise right heart catheterisation before and after pulmonary endarterectomy in patients with chronic thromboembolic disease. European Respiratory Journal, 2018, 52, 1800458.	6.7	57
129	Nintedanib in Severe Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 808-810.	5.6	17
130	More on Single-Beat Estimation of Right Ventriculoarterial Coupling in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 816-818.	5.6	63
131	De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures. American Journal of Human Genetics, 2018, 103, 144-153.	6.2	36
132	Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding. BioMed Research International, 2018, 2018, 1-9.	1.9	29
133	Hypoxic pulmonary vasoconstriction in isolated mouse pulmonary arterial vessels. Experimental Physiology, 2018, 103, 1185-1191.	2.0	14
134	Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2018, 8, 1-7.	1.7	44
135	Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension. Journal of Heart and Lung Transplantation, 2018, 37, 1235-1244.	0.6	26
136	Inflammatory Mediators Drive Adverse Right Ventricular Remodeling and Dysfunction and Serve as Potential Biomarkers. Frontiers in Physiology, 2018, 9, 609.	2.8	42
137	Switching inhaled iloprost formulations in patients with pulmonary arterial hypertension: the VENTASWITCH Trial. Pulmonary Circulation, 2018, 8, 1-7.	1.7	5
138	Relevance of the TAPSE/PASP ratio in pulmonary arterial hypertension. International Journal of Cardiology, 2018, 266, 229-235.	1.7	154
139	Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. PLoS ONE, 2018, 13, e0193226.	2.5	33
140	Effects on Right Ventricular size and function by Riociguat in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension (The RIVER Study). , 2018, , .		0
141	PEGASUS - the effects of commercial air travel on patients suffering from pulmonary hypertension - a prospective, multicenter, multinational study. , 2018, , .		0
142	Acute response of iloprost inhalation using the Breelib nebulizer in pulmonary arterial hypertension: the Breelib acute study. , 2018, , .		0
143	Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. , 2018, , .		2
144	Effects of electronic cigarette aerosol on isolated murine lung cells and bronchoalveolar lavage fluid. , 2018, , .		0

#	Article	IF	Citations
145	Diagnostic accuracy of echocardiography in pulmonary hypertension due to interstitial lung disease. , 2018, , .		0
146	EARLIER: End tidal carbon dioxide for earlier detection of pulmonary hypertension. , 2018, , .		0
147	The prognostic relevance of oxygen uptake in inoperable chronic thromboembolic pulmonary hypertension. Clinical Respiratory Journal, 2017, 11, 682-690.	1.6	7
148	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. Chest, 2017, 151, 468-480.	0.8	79
149	Comparison of hemodynamic parameters in treatment-naÃ¯ve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. Journal of Heart and Lung Transplantation, 2017, 36, 509-519.	0.6	22
150	The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups. Journal of Heart and Lung Transplantation, 2017, 36, 957-967.	0.6	221
151	Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Annals of the Rheumatic Diseases, 2017, 76, 1219-1227.	0.9	135
152	Hemodynamic phenotyping based on exercise catheterization predicts outcome in patients with heart failure and reduced ejection fraction. Journal of Heart and Lung Transplantation, 2017, 36, 880-889.	0.6	16
153	Amplified canonical transforming growth factor-Î² signalling via heat shock protein 90 in pulmonary fibrosis. European Respiratory Journal, 2017, 49, 1501941.	6.7	66
154	Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Annals of the Rheumatic Diseases, 2017, 76, 422-426.	0.9	108
155	Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension. Heart, 2017, 103, 599-606.	2.9	34
156	Intravenous treprostinil infusion via a fully implantable pump for pulmonary arterial hypertension. Clinical Research in Cardiology, 2017, 106, 776-783.	3.3	18
157	Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study. Respiratory Medicine, 2017, 128, 50-56.	2.9	31
158	Inspiratory capacity is not altered in operable chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2017, 7, 543-546.	1.7	2
159	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. Lancet Respiratory Medicine,the, 2017, 5, 717-726.	10.7	99
160	Mitochondrial Complex IV Subunit 4 Isoform 2 Is Essential for Acute Pulmonary Oxygen Sensing. Circulation Research, 2017, 121, 424-438.	4.5	90
161	Plasma MMP2/TIMP4 Ratio at Follow-up Assessment Predicts Disease Progression of Idiopathic Pulmonary Arterial Hypertension. Lung, 2017, 195, 489-496.	3.3	24
162	Pulmonary artery to aorta ratio and risk of all-cause mortality in the general population: the Rotterdam Study. European Respiratory Journal, 2017, 49, 1602168.	6.7	29

#	Article	IF	Citations
163	Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Respiratory Medicine, 2017, 129, 124-129.	2.9	11
164	Effects of exercise training on pulmonary hemodynamics, functional capacity and inflammation in pulmonary hypertension. Pulmonary Circulation, 2017, 7, 20-37.	1.7	33
165	Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. European Respiratory Journal, 2017, 49, 1602409.	6.7	178
166	The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 505-513.	1.7	20
167	Medical management of chronic thromboembolic pulmonary hypertension. European Respiratory Review, 2017, 26, 160107.	7.1	52
168	Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. European Respiratory Review, 2017, 26, 160119.	7.1	183
169	Maintained right ventricular pressure overload induces ventriculaâ€“arterial decoupling in mice. Experimental Physiology, 2017, 102, 180-189.	2.0	18
170	Pulmonary function and diffusion capacity are associated with pulmonary arterial systolic pressure in the general population: The Rotterdam Study. Respiratory Medicine, 2017, 132, 50-55.	2.9	6
171	Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1602493.	6.7	97
172	Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respiratory Medicine,the, 2017, 5, 785-794.	10.7	201
173	RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. European Respiratory Journal, 2017, 50, 1602425.	6.7	113
174	Tidal Carbon Dioxide as a Prognostic Feature in Inoperable Chronic Thromboembolic Pulmonary Hypertension. Annals of the American Thoracic Society, 2017, 14, 1603-1604.	3.2	0
175	Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. European Respiratory Journal, 2017, 50, 1700740.	6.7	489
176	Lung cancerâ€“associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cellâ€“immune cell cross-talk. Science Translational Medicine, 2017, 9, .	12.4	69
177	p38 MAPK Inhibition Improves Heart Function in Pressure-Loaded Right Ventricular Hypertrophy. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 603-614.	2.9	72
178	Macitentan Improves Health-Related QualityÂof Life for Patients With Pulmonary Arterial Hypertension. Chest, 2017, 151, 106-118.	0.8	46
179	Procedural safety of a fully implantable intravenous prostanoid pump for pulmonary hypertension. Clinical Research in Cardiology, 2017, 106, 174-182.	3.3	16
180	Effect of Riociguat on Pulmonary Arterial Compliance in Patients With Pulmonary Arterial Hypertension (PAH) in the Respite Study. Chest, 2017, 152, A1005-A1006.	0.8	0

#	Article	IF	Citations
181	SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. European Heart Journal, 2017, 38, 1147-1155.	2.2	65
182	The Role of Transient Receptor Potential Channel 6 Channels in the Pulmonary Vasculature. Frontiers in Immunology, 2017, 8, 707.	4.8	39
183	Follow-Up (Measurement) of Corrected QT Interval in Adult Patients before and after Lung Transplantation. BioMed Research International, 2017, 2017, 1-5.	1.9	1
184	Thin Air Resulting in High Pressure: Mountain Sickness and Hypoxia-Induced Pulmonary Hypertension. Canadian Respiratory Journal, 2017, 2017, 1-17.	1.6	32
185	Pressure overload leads to an increased accumulation and activity of mast cells in the right ventricle. Physiological Reports, 2017, 5, e13146.	1.7	36
186	Macitentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): results from the randomised controlled MERIT study. , 2017, , .		9
187	Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension. Oncotarget, 2017, 8, 29613-29624.	1.8	9
188	Pulmonary Hypertension. Deutsches Ärzteblatt International, 2017, 114, 73-84.	0.9	87
189	Pulmonary arterial hypertension-related morbidity is prognostic for survival: insights from the SERAPHIN and GRIPHON studies. , 2017, , .		0
190	VENTASWITCH study: Switching from Ventavis (iloprost) V10 to V20 improves inhalation behaviour in patients with pulmonary arterial hypertension (PAH). , 2017, , .		0
191	Prognostic Relevance of Nonsustained Ventricular Tachycardia in Patients with Pulmonary Hypertension. BioMed Research International, 2016, 2016, 1-7.	1.9	12
192	Heart rate response during 6-minute walking testing predicts outcome in operable chronic thromboembolic pulmonary hypertension. BMC Pulmonary Medicine, 2016, 16, 96.	2.0	12
193	Quality of life in patients with chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2016, 48, 526-537.	6.7	52
194	Relevance of Angiopoietinâ€2 and Soluble Pâ€Selectin Levels in Patients with Pulmonary Arterial Hypertension Receiving Combination Therapy with Oral Treprostinil: A FREEDOMâ€C2 Biomarker Substudy. Pulmonary Circulation, 2016, 6, 516-523.	1.7	7
195	Effects of Riociguat in Treatment-Naive vs Pretreated Patients With Pulmonary Arterial Hypertension: 2-Year Efficacy Results From the PATENT-2 Study. Chest, 2016, 150, 1162A.	0.8	1
196	The Clinical Impact of Referral Time in Patients With Pulmonary Hypertension on Disease Progression: A Register Analysis of a Tertiary Referral Center. Chest, 2016, 150, 1169A.	0.8	0
197	COPD-associated pulmonary hypertension: clinical implications and current methods for treatment. Expert Review of Respiratory Medicine, 2016, 10, 755-766.	2.5	5
198	Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respiratory Medicine,the, 2016, 4, 361-371.	10.7	97

#	Article	IF	Citations
199	Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. Lancet Respiratory Medicine,the, 2016, 4, 372-380.	10.7	130
200	Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respiratory Medicine,the, 2016, 4, 894-901.	10.7	59
201	Selexipag for the treatment of pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy, 2016, 17, 1825-1834.	1.8	3
202	Traditional and new composite endpoints inÂheart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. European Journal of Heart Failure, 2016, 18, 482-489.	7.1	74
203	Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension. European Respiratory Journal, 2016, 48, 1137-1149.	6.7	89
204	Biomarkers of tissue remodeling predict survival in patients with pulmonary hypertension. International Journal of Cardiology, 2016, 223, 821-826.	1.7	20
205	Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study. Journal of Thrombosis and Thrombolysis, 2016, 42, 600-609.	2.1	50
206	The prognostic impact of thyroid function in pulmonary hypertension. Journal of Heart and Lung Transplantation, 2016, 35, 1427-1434.	0.6	25
207	Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study. BMC Pulmonary Medicine, 2016, 16, 5.	2.0	12
208	Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice. International Journal of Cardiology, 2016, 216, 85-91.	1.7	28
209	Prolonged vasodilatory response to nanoencapsulated sildenafil in pulmonary hypertension. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 63-68.	3.3	19
210	Effects of carbon monoxide-releasing molecules on pulmonary vasoreactivity in isolated perfused lungs. Journal of Applied Physiology, 2016, 120, 271-281.	2.5	9
211	miR-223â€“IGF-IR signalling in hypoxia- and load-induced right-ventricular failure: a novel therapeutic approach. Cardiovascular Research, 2016, 111, 184-193.	3.8	54
212	2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Revista Espanola De Cardiologia (English Ed), 2016, 69, 177.	0.6	210
213	The molecular targets of approved treatments for pulmonary arterial hypertension. Thorax, 2016, 71, 73-83.	5.6	126
214	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal, 2016, 37, 67-119.	2.2	5,074
215	The Clinical Significance of HbA1c in Operable Chronic Thromboembolic Pulmonary Hypertension. PLoS ONE, 2016, 11, e0152580.	2.5	8
216	Circulating Angiopoietin-1 Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary Hypertension. PLoS ONE, 2016, 11, e0165982.	2.5	10

#	Article	IF	Citations
217	2015 ESC/ERS GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION. Russian Journal of Cardiology, 2016, , 5-64.	1.4	15
218	Evaluation of the prognostic value of electrocardiography parameters and heart rhythm in patients with pulmonary hypertension. Cardiology Journal, 2016, 23, 465-472.	1.2	23
219	Procedural safety of a fully implantable pump for delivery of intravenous prostanoids in severe pulmonary hypertension: A two-center observational study. , 2016, , .		0
220	Anti-fibrotic effects of pirfenidone on pulmonary arterial vascular smooth muscle cells. , 2016, , .		0
221	Individualized Dosing of Selexipag Based on Tolerability in the GRIPHON Study Shows Consistent Efficacy and Safety in Patients With Pulmonary Arterial Hypertension (PAH). Chest, 2015, 148, 961A.	0.8	3
222	Riociguat in Combination With Prostacyclin Analogs for the Treatment of Pulmonary Arterial Hypertension (PAH): A Subgroup Analysis of the PATENT Studies. Chest, 2015, 148, 922A.	0.8	2
223	Application of REVEAL Risk Score to Patients With PAH Receiving Riociguat in the PATENT-2 Study. Chest, 2015, 148, 930A.	0.8	0
224	Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. European Respiratory Journal, 2015, 46, 1711-1720.	6.7	39
225	Heart Rate Variability is Related to Disease Severity in Children and Young Adults with Pulmonary Hypertension. Frontiers in Pediatrics, 2015, 3, 63.	1.9	14
226	5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure. BioMed Research International, 2015, 2015, 1-8.	1.9	62
227	Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart, 2015, 101, 1792-1799.	2.9	87
228	Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2015, 373, 2522-2533.	27.0	790
229	Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2015, 34, 1366-1375.	0.6	103
230	Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). European Respiratory Journal, 2015, 45, 1303-1313.	6.7	174
231	Pathophysiology and Treatment of High-Altitude Pulmonary Vascular Disease. Circulation, 2015, 131, 582-590.	1.6	108
232	Acute Hemodynamic Effects of Nebulized Iloprost via the Iâ€Neb Adaptive Aerosol Delivery System in Pulmonary Hypertension. Pulmonary Circulation, 2015, 5, 162-170.	1.7	12
233	Sildenafil versus Nitric Oxide for Acute Vasodilator Testing in Pulmonary Arterial Hypertension. Pulmonary Circulation, 2015, 5, 305-312.	1.7	15
234	Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study. Journal of Heart and Lung Transplantation, 2015, 34, 338-347.	0.6	10

#	Article	IF	Citations
235	Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study. Journal of Heart and Lung Transplantation, 2015, 34, 348-355.	0.6	13
236	Acute Effects of Riociguat in Borderline or Manifest Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease. Pulmonary Circulation, 2015, 5, 296-304.	1.7	31
237	Pulmonary Hemodynamic Response to Exercise in Chronic Thromboembolic Pulmonary Hypertension before and after Pulmonary Endarterectomy. Respiration, 2015, 90, 63-73.	2.6	21
238	Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. European Respiratory Journal, 2015, 46, 405-413.	6.7	184
239	Chymase: a multifunctional player in pulmonary hypertension associated with lung fibrosis. European Respiratory Journal, 2015, 46, 1084-1094.	6.7	45
240	Effect of Selexipag on Morbidity/Mortality in Pulmonary Arterial Hypertension: Results of the GRIPHON Study. Journal of Heart and Lung Transplantation, 2015, 34, S163.	0.6	2
241	Poor sleep quality is associated with exercise limitation in precapillary pulmonary hypertension. BMC Pulmonary Medicine, 2015, 15, 11.	2.0	6
242	Ventricular tachycardias in patients with pulmonary hypertension: an underestimated prevalence? A prospective clinical study. Herzschrittmachertherapie Und Elektrophysiologie, 2015, 26, 155-162.	0.8	13
243	New potential diagnostic biomarkers for pulmonary hypertension. European Respiratory Journal, 2015, 46, 1390-1396.	6.7	32
244	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal, 2015, 46, 903-975.	6.7	2,415
245	Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2015, 373, 834-844.	27.0	906
246	Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). European Respiratory Journal, 2015, 45, 1293-1302.	6.7	247
247	Effect of Macitentan on Hospitalizations. JACC: Heart Failure, 2015, 3, 1-8.	4.1	51
248	Resistant Hypertension. Cardiology Clinics, 2015, 33, 75-87.	2.2	7
249	Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naÃ¯ve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population. , 2015, , .		2
250	Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice. PLoS ONE, 2015, 10, e0129327.	2.5	29
251	Prevalence of Pulmonary Hypertension in the General Population: The Rotterdam Study. PLoS ONE, 2015, 10, e0130072.	2.5	57
252	Definition, Klassifikation und Diagnose der pulmonalen Hypertonie (PH). Atemwegs- Und Lungenkrankheiten, 2015, 41, 166-170.	0.0	0

#	Article	IF	Citations
253	Chronisch thromboembolische pulmonale Hypertonie. Atemwegs- Und Lungenkrankheiten, 2015, 41, 198-203.	0.0	0
254	Therapie der pulmonal-arteriellen Hypertonie. Atemwegs- Und Lungenkrankheiten, 2015, 41, 171-178.	0.0	0
255	Effects of apoptosis signal- regulating kinase 1 (ASK1) inhibition in experimental pressure overload-induced right ventricular dysfunction. , 2015, , .		0
256	Response to Letters Regarding Article, â€œAnticoagulation and Survival in Pulmonary Arterial Hypertension: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)â€. Circulation, 2014, 130, e110-2.	1.6	5
257	Electrophysiological Studies in Patients with Pulmonary Hypertension: A Retrospective Investigation. BioMed Research International, 2014, 2014, 1-6.	1.9	13
258	Histological Characterization of Mast Cell Chymase in Patients with Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease. Pulmonary Circulation, 2014, 4, 128-136.	1.7	36
259	Anticoagulation and Survival in Pulmonary Arterial Hypertension. Circulation, 2014, 129, 57-65.	1.6	317
260	Stimulation of Soluble Guanylate Cyclase Prevents Cigarette Smokeâ€“induced Pulmonary Hypertension and Emphysema. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1359-1373.	5.6	80
261	Structural and functional prevention of hypoxia-induced pulmonary hypertension by individualized exercise training in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2014, 306, L986-L995.	2.9	31
262	The role of combination therapy in managing pulmonary arterial hypertension. European Respiratory Review, 2014, 23, 469-475.	7.1	44
263	Arterial hypertension in a murine model of sleep apnea. Journal of Hypertension, 2014, 32, 300-305.	0.5	47
264	The Prognostic Significance of Inspiratory Capacity in Pulmonary Arterial Hypertension. Respiration, 2014, 88, 24-30.	2.6	16
265	Interaction of ambrisentan and phenprocoumon in patients with pulmonary hypertension. Pulmonary Pharmacology and Therapeutics, 2014, 28, 87-89.	2.6	6
266	Impact of S-Adenosylmethionine Decarboxylase 1 on Pulmonary Vascular Remodeling. Circulation, 2014, 129, 1510-1523.	1.6	23
267	Vascular Receptor Autoantibodies in Pulmonary Arterial Hypertension Associated with Systemic Sclerosis. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 808-817.	5.6	170
268	Novel and Emerging Therapies for Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 394-400.	5.6	75
269	Long-term Riociguat Treatment in PAH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 12-Week Phase III PATENT-1 Study and PATENT-2 Open-Label Extension. Chest, 2014, 145, 513A.	0.8	3
270	Long-term Riociguat Treatment in Inoperable and Persistent/Recurrent CTEPH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 16-Week Phase III CHEST-1 Study and CHEST-2 Open-Label Extension. Chest, 2014, 145, 535B.	0.8	4

#	Article	IF	Citations
271	Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. New England Journal of Medicine, 2013, 369, 319-329.	27.0	1,144
272	Riociguat for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 330-340.	27.0	1,120
273	Mitochondrial Hyperpolarization in Pulmonary Vascular Remodeling. Mitochondrial Uncoupling Protein Deficiency as Disease Model. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 358-367.	2.9	66
274	Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 809-818.	27.0	1,168
275	Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling. International Journal of Cardiology, 2013, 167, 2630-2637.	1.7	35
276	Updated Clinical Classification of Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D34-D41.	2.8	2,865
277	Function of NADPH Oxidase 1 in Pulmonary Arterial Smooth Muscle Cells After Monocrotaline-Induced Pulmonary Vascular Remodeling. Antioxidants and Redox Signaling, 2013, 19, 2213-2231.	5.4	62
278	Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular Dysfunction. Circulation, 2013, 128, 502-511.	1.6	286
279	Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension. Circulation, 2013, 127, 1128-1138.	1.6	482
280	Cofilin, a hypoxiaâ€regulated protein in murine lungs identified by 2<scp>DE</scp>: Role of the cytoskeletal protein cofilin in pulmonary hypertension. Proteomics, 2013, 13, 75-88.	2.2	16
281	New Trial Designs and Potential Therapies for Pulmonary Artery Hypertension. Journal of the American College of Cardiology, 2013, 62, D82-D91.	2.8	113
282	Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. International Journal of Cardiology, 2013, 168, 871-880.	1.7	357
283	Riociguat for Pulmonary Hypertension. New England Journal of Medicine, 2013, 369, 2266-2268.	27.0	21
284	Sleep apnea in precapillary pulmonary hypertension. Sleep Medicine, 2013, 14, 247-251.	1.6	75
285	Reduced MicroRNA-150 Is Associated with Poor Survival in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 294-302.	5.6	153
286	Effects of Dimethylarginine Dimethylaminohydrolaseâ€“1 Overexpression on the Response of the Pulmonary Vasculature to Hypoxia. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 491-500.	2.9	17
287	New horizons in pulmonary arterial hypertension therapies. European Respiratory Review, 2013, 22, 503-514.	7.1	36
288	Classical Transient Receptor Potential Channel 1 in Hypoxia-induced Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1451-1459.	5.6	77

#	Article	IF	Citations
289	Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Respiratory Research, 2013, 14, 104.	3.6	83
290	Updating Clinical Endpoint Definitions. Pulmonary Circulation, 2013, 3, 206-216.	1.7	22
291	Shortâ€Term Improvement in Pulmonary Hemodynamics is Strongly Predictive of Longâ€Term Survival in Patients with Pulmonary Arterial Hypertension. Pulmonary Circulation, 2013, 3, 523-532.	1.7	20
292	Riociguat for the Treatment of Pulmonary Arterial Hypertension (PAH): 1-Year Results from the PATENT-2 Long-term Extension Study. Chest, 2013, 144, 1024A.	0.8	4
293	Do parameters of cardiac function predict long-term outcomes in patients with pulmonary arterial hypertension? Data from SERAPHIN, a randomized controlled study of macitentan. Chest, 2013, 144, 870B.	0.8	0
294	Association Between WHO Functional Class and Long-term Prognosis in Patients With Pulmonary Arterial Hypertension: Data From SERAPHIN, A Randomized Controlled Study of Macitentan. Chest, 2013, 144, 879A.	0.8	1
295	Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): 1-Year Results from the CHEST-2 Long-term Extension Study. Chest, 2013, 144, 1023A.	0.8	5
296	Mast cell chymase: an indispensable instrument in the pathological symphony of idiopathic pulmonary fibrosis?. Histology and Histopathology, 2013, 28, 691-9.	0.7	15
297	Cardiovocal Syndrome (Ortner's Syndrome) Associated with Chronic Thromboembolic Pulmonary Hypertension and Giant Pulmonary Artery Aneurysm: Case Report and Review of the Literature. Case Reports in Medicine, 2012, 2012, 1-5.	0.7	22
298	Role of Src Tyrosine Kinases in Experimental Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 1354-1365.	2.4	108
299	Inhibition of MicroRNA-17 Improves Lung and Heart Function in Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 409-419.	5.6	206
300	A Case Series of Patients with Severe Pulmonary Hypertension Receiving an Implantable Pump for Intravenous Prostanoid Therapy. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 1196-1198.	5.6	24
301	Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. European Journal of Heart Failure, 2012, 14, 946-953.	7.1	25
302	Diagnosis of CTEPH versus IPAH using capillary to end-tidal carbon dioxide gradients. European Respiratory Journal, 2012, 39, 119-124.	6.7	60
303	PAR-2 Inhibition Reverses Experimental Pulmonary Hypertension. Circulation Research, 2012, 110, 1179-1191.	4.5	61
304	Tadalafil for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2012, 60, 768-774.	2.8	124
305	Immune and Inflammatory Cell Involvement in the Pathology of Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 897-908.	5.6	296
306	Activation of TRPC6 channels is essential for lung ischaemiaâ€“reperfusion induced oedema in mice. Nature Communications, 2012, 3, 649.	12.8	162

#	Article	IF	Citations
307	Dynamic hyperinflation during exercise in patients with precapillary pulmonary hypertension. Respiratory Medicine, 2012, 106, 308-313.	2.9	29
308	HbA1c in pulmonary arterial hypertension: A marker of prognostic relevance?. Journal of Heart and Lung Transplantation, 2012, 31, 1109-1114.	0.6	33
309	Safety and efficacy of exercise training in various forms of pulmonary hypertension. European Respiratory Journal, 2012, 40, 84-92.	6.7	199
310	The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats. PLoS ONE, 2012, 7, e43433.	2.5	100
311	Hypoxia induces Kv channel current inhibition by increased NADPH oxidase-derived reactive oxygen species. Free Radical Biology and Medicine, 2012, 52, 1033-1042.	2.9	68
312	Effects of hypercapnia and NO synthase inhibition in sustained hypoxic pulmonary vasoconstriction. Respiratory Research, 2012, 13, 7.	3.6	20
313	Mechanisms of disease: pulmonary arterial hypertension. Nature Reviews Cardiology, 2011, 8, 443-455.	13.7	605
314	Effect of Exercise and Respiratory Training on Clinical Progression and Survival in Patients with Severe Chronic Pulmonary Hypertension. Respiration, 2011, 81, 394-401.	2.6	151
315	Riociguat for the treatment of pulmonary hypertension. Expert Opinion on Investigational Drugs, 2011, 20, 567-576.	4.1	81
316	Inducible NOS Inhibition Reverses Tobacco-Smoke-Induced Emphysema and Pulmonary Hypertension in Mice. Cell, 2011, 147, 293-305.	28.9	293
317	Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2011, 30, 632-643.	0.6	95
318	A retrospective review of long anterior fusions to the sacrum. Spine Journal, 2011, 11, 290-294.	1.3	11
319	Cologne Consensus Conference on pulmonary hypertension. International Journal of Cardiology, 2011, 154, S1-S2.	1.7	4
320	Treatment of pulmonary arterial hypertension (PAH): Updated Recommendations of the Cologne Consensus Conference 2011. International Journal of Cardiology, 2011, 154, S20-S33.	1.7	46
321	Pulmonary hypertension due to chronic lung disease: Updated Recommendations of the Cologne Consensus Conference 2011. International Journal of Cardiology, 2011, 154, S45-S53.	1.7	61
322	Combination Therapy With Sildenafil And Sitaxentan In Patients With Severe Pulmonary Hypertension. , 2011, , .		0
323	Role Of Notch Signaling In Pulmonary Arterial Hypertension. , 2011, , .		0
324	Prevention Of Experimental Hypoxia-Induced Pulmonary Hypertension By Moderate Exercise Training In Mice. , 2011, , .		0

#	Article	IF	Citations
325	Mitochondrial Alterations Of Pulmonary Arterial Smooth Muscle Cells In Pulmonary Hypertension. , 2011, , .		0
326	Phosphodiesterase 10A Upregulation Contributes to Pulmonary Vascular Remodeling. PLoS ONE, 2011, 6, e18136.	2.5	36
327	Contribution Of Progenitor Cells In Experimental Right Heart Hypertrophy Induced By Pulmonary Artery Ligation. , 2011, , .		0
328	Psoas Muscle Architectural Design, In Vivo Sarcomere Length Range, and Passive Tensile Properties Support Its Role as a Lumbar Spine Stabilizer. Spine, 2011, 36, E1666-E1674.	2.0	48
329	Effects Of Riociguat On Pulmonary Vascular Remodeling In Severe Experimental Pulmonary Hypertension. , 2011, , .		1
330	Effects Of The Soluble Guanylate Cyclase Stimulator Riociguat On Emphysema Development In Tobacco-Smoke Exposed Mice. , 2011, , .		0
331	Inflammation, immunological reaction and role of infection in pulmonary hypertension. Clinical Microbiology and Infection, 2011, 17, 7-14.	6.0	75
332	Stem cellâ€mediated natural tissue engineering. Journal of Cellular and Molecular Medicine, 2011, 15, 52-62.	3.6	10
333	Effects of riociguat in severe experimental pulmonary hypertension. BMC Pharmacology, 2011, 11, .	0.4	0
334	The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. BMC Pharmacology, 2011, 11, .	0.4	0
335	Improvement of right heart structure and function by BAY 41-8543 in pulmonary artery banded mice. BMC Pharmacology, 2011, 11, .	0.4	1
336	Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy. BMC Pulmonary Medicine, 2011, 11, 56.	2.0	16
337	Diacylglycerol regulates acute hypoxic pulmonary vasoconstriction via TRPC6. Respiratory Research, 2011, 12, 20.	3.6	51
338	Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. Respiratory Research, 2011, 12, 60.	3.6	66
339	Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension. Respiratory Research, 2011, 12, 87.	3.6	17
340	Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations. Respiratory Research, 2011, 12, 99.	3.6	59
341	cAMP Phosphodiesterase Inhibitors Increases Nitric Oxide Production by Modulating Dimethylarginine Dimethylaminohydrolases. Circulation, 2011, 123, 1194-1204.	1.6	42
342	Hypoxic Pulmonary Hypertension in Mice with Constitutively Active Plateletâ€Derived Growth Factor Receptorâ€Î²2. Pulmonary Circulation, 2011, 1, 259-268.	1.7	44

#	Article	IF	Citations
343	Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. European Respiratory Journal, 2011, 37, 1104-1118.	6.7	93
344	Long-term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension. Chest, 2011, 140, 1274-1283.	0.8	237
345	The Role of Dimethylarginine Dimethylaminohydrolase in Idiopathic Pulmonary Fibrosis. Science Translational Medicine, 2011, 03, 87ra53.	12.4	59
346	Air Travel Can Be Safe and Well Tolerated in Patients with Clinically Stable Pulmonary Hypertension. Pulmonary Circulation, 2011, 1, 239-243.	1.7	21
347	Glycogen Synthase Kinase 3beta Contributes to Proliferation of Arterial Smooth Muscle Cells in Pulmonary Hypertension. PLoS ONE, 2011, 6, e18883.	2.5	36
348	An Evaluation of Fracture Stabilization Comparing Kyphoplasty and Titanium Mesh Repair Techniques for Vertebral Compression Fractures. Spine, 2010, 35, E768-E773.	2.0	22
349	Phosphodiesterase 10A Upregulation Contributes To Pulmonary Vascular Remodeling. , 2010, , .		0
350	Effects Of Inhaled Aviptadil (Vasoactive Intestinal Peptide) In Patients With Pulmonary Arterial Hypertension (PAH). , 2010, , .		5
351	Updated classification and management of pulmonary hypertension. Heart, 2010, 96, 552-559.	2.9	44
352	Redox signaling and reactive oxygen species in hypoxic pulmonary vasoconstriction. Respiratory Physiology and Neurobiology, 2010, 174, 282-291.	1.6	35
353	Role of Reactive Oxygen Species in Acute Pulmonary Oxygen Sensing. Free Radical Biology and Medicine, 2010, 49, S48.	2.9	0
354	Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. BMC Pulmonary Medicine, 2010, 10, 26.	2.0	38
355	Targeting non-malignant disorders with tyrosine kinase inhibitors. Nature Reviews Drug Discovery, 2010, 9, 956-970.	46.4	118
356	Long Term Use Of Imatinib In Patients With Severe Pulmonary Arterial Hypertension. , 2010, , .		2
357	Exercise Induced Pulmonary Hypertension Associated With Systemic Sclerosis: Four Distinct Entities. , 2010, , .		0
358	Effects Of The Multikinase Inhibitor Sunitinib On Right Ventricular Remodeling In An Experimental Model Of Right Heart Hypertrophy. , 2010, , .		0
359	Does Sitaxsentan Therapy Offer Benefit To Functional Class II Patients With Pulmonary Arterial Hypertension. , 2010, , .		0
360	Reversal Of Experimental Pulmonary Hypertension By The Multi-kinase Inhibitor Sunitinib. , 2010, , .		0

#	Article	IF	Citations
361	Combined Inhibition Of 5-HT2a And 5-HT2b-receptor Ameliorates Myocardial Hypertrophy And Diastolic Dysfunction In The Pressure Overloaded Right Heart. , 2010, , .		0
362	A Highly Selective Endothelin-A Receptor Antagonist TBC3711 Reverses Monocrotaline Induced Pulmonary Hypertension. , 2010, , .		0
363	Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension. European Respiratory Journal, 2010, 36, 808-818.	6.7	48
364	Role of Epidermal Growth Factor Inhibition in Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 158-167.	5.6	118
365	Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. European Respiratory Journal, 2010, 36, 792-799.	6.7	212
366	Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1171-1177.	5.6	331
367	Mitochondrial cytochrome redox states and respiration in acute pulmonary oxygen sensing. European Respiratory Journal, 2010, 36, 1056-1066.	6.7	34
368	Update on Pulmonary Hypertension 2009. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1020-1026.	5.6	15
369	Animal models of pulmonary hypertension: role in translational research. Drug Discovery Today: Disease Models, 2010, 7, 89-97.	1.2	11
370	Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis. Respiratory Research, 2010, 11, 146.	3.6	22
371	Nebulization of the acidified sodium nitrite formulation attenuates acute hypoxic pulmonary vasoconstriction. Respiratory Research, 2010, 11, 81.	3.6	13
372	Burden of pulmonary arterial hypertension in Germany. Respiratory Medicine, 2010, 104, 902-910.	2.9	43
373	Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respiratory Medicine, 2010, 104, 731-740.	2.9	72
374	Identification of right heart-enriched genes in a murine model of chronic outflow tract obstruction. Journal of Molecular and Cellular Cardiology, 2010, 49, 598-605.	1.9	56
375	Riociguat for pulmonary hypertension. Future Cardiology, 2010, 6, 155-166.	1.2	30
376	Targeting cancer with phosphodiesterase inhibitors. Expert Opinion on Investigational Drugs, 2010, 19, 117-131.	4.1	123
377	Simvastatin as a Treatment for Pulmonary Hypertension Trial. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1106-1113.	5.6	112
378	Classical transient receptor potential channel 6 (TRPC6) is essential for ischemiaâ€reperfusion injury of the lung. FASEB Journal, 2010, 24, 591.2.	0.5	0

#	Article	IF	Citations
379	IMATINIB MESYLATE TREATMENT FOR SEVERE PULMONARY ARTERIAL HYPERTENSION: A PROPOSED PHASE III 24-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED CLINICAL TRIAL. Chest, 2009, 136, 64S.	0.8	1
380	Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension. Circulation, 2009, 119, 1747-1757.	1.6	205
381	Expression and Activity of Phosphodiesterase Isoforms during Epithelial Mesenchymal Transition: The Role of Phosphodiesterase 4. Molecular Biology of the Cell, 2009, 20, 4751-4765.	2.1	84
382	Response to Letter Regarding Article, â€œPulmonary Vascular Disease in the Developing Worldâ€• Circulation, 2009, 120, .	1.6	0
383	Heme Oxygenase-2 and Large-Conductance Ca2+-activated K+Channels. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 353-364.	5.6	37
384	A Functional Single-Nucleotide Polymorphism in theTRPC6Gene Promoter Associated With Idiopathic Pulmonary Arterial Hypertension. Circulation, 2009, 119, 2313-2322.	1.6	173
385	Effects of hypercapnia with and without acidosis on hypoxic pulmonary vasoconstriction. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 297, L977-L983.	2.9	60
386	The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 297, L658-L665.	2.9	35
387	Novel soluble guanylyl cyclase stimulator BAY 41-2272 attenuates ischemia-reperfusion-induced lung injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 296, L462-L469.	2.9	20
388	Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia. European Respiratory Journal, 2009, 33, 861-870.	6.7	42
389	Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. European Respiratory Journal, 2009, 34, 132-137.	6.7	83
390	Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure. BMC Pharmacology, 2009, 9, .	0.4	15
391	Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH). BMC Pharmacology, 2009, 9, .	0.4	2
392	The science of endothelinâ€1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies. European Journal of Clinical Investigation, 2009, 39, 38-49.	3.4	44
393	Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. Pulmonary Pharmacology and Therapeutics, 2009, 22, 50-56.	2.6	43
394	Noninvasive detection of early pulmonary vascular dysfunction in scleroderma. Respiratory Medicine, 2009, 103, 1713-1718.	2.9	29
395	Future Perspectives for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S108-S117.	2.8	62
396	Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S78-S84.	2.8	463

#	Article	IF	Citations
397	Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, 1971-1981.	2.8	227
398	Tadalafil Therapy for Pulmonary Arterial Hypertension. Circulation, 2009, 119, 2894-2903.	1.6	956
399	Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. European Respiratory Review, 2009, 18, 35-41.	7.1	55
400	First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. European Respiratory Journal, 2009, 33, 785-792.	6.7	216
401	Modulating cGMP to Treat Lung Diseases. Handbook of Experimental Pharmacology, 2009, , 469-483.	1.8	14
402	Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury. BMC Pulmonary Medicine, 2008, 8, 25.	2.0	36
403	Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of the American College of Cardiology, 2008, 52, 2127-2134.	2.8	506
404	Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulmonary Pharmacology and Therapeutics, 2008, 21, 824-832.	2.6	64
405	Regulation of hypoxic pulmonary vasoconstriction: basic mechanisms. European Respiratory Journal, 2008, 32, 1639-1651.	6.7	184
406	Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. European Respiratory Journal, 2008, 32, 881-891.	6.7	216
407	Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure. European Respiratory Review, 2008, 17, 72-73.	7.1	0
408	Uncertainties in the Diagnosis and Treatment of Pulmonary Arterial Hypertension. Circulation, 2008, 118, 1195-1201.	1.6	90
409	Fhl-1, a New Key Protein in Pulmonary Hypertension. Circulation, 2008, 118, 1183-1194.	1.6	79
410	Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. European Respiratory Journal, 2008, 32, 198-209.	6.7	129
411	Ambrisentan for the Treatment of Pulmonary Arterial Hypertension. Circulation, 2008, 117, 3010-3019.	1.6	967
412	Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling. Circulation, 2008, 118, 2081-2090.	1.6	139
413	Pulmonary Vascular Disease in the Developing World. Circulation, 2008, 118, 1758-1766.	1.6	97
414	Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition. European Respiratory Journal, 2008, 31, 599-610.	6.7	28

#	Article	IF	Citations
415	Role of the Prostanoid EP4 Receptor in Iloprost-mediated Vasodilatation in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 188-196.	5.6	82
416	Impairment of respiratory muscle function in pulmonary hypertension. Clinical Science, 2008, 114, 165-171.	4.3	72
417	The lectin-like domain of tumor necrosis factor-Î± improves alveolar fluid balance in injured isolated rabbit lungs*. Critical Care Medicine, 2008, 36, 1543-1550.	0.9	61
418	Hypoxia-Dependent Regulation of Nonphagocytic NADPH Oxidase Subunit NOX4 in the Pulmonary Vasculature. Circulation Research, 2007, 101, 258-267.	4.5	317
419	Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2007, 30, 922-927.	6.7	163
420	Phosphodiesterase 1 Upregulation in Pulmonary Arterial Hypertension. Circulation, 2007, 115, 2331-2339.	1.6	139
421	A Combination Hybrid-Based Vaccination/Adoptive Cellular Therapy to Prevent Tumor Growth by Involvement of T Cells. Cancer Research, 2007, 67, 5443-5453.	0.9	26
422	Microcirculatory Dysfunction in the Brain Precedes Changes in Evoked Potentials in Endotoxin-Induced Sepsis Syndrome in Rats. Cerebrovascular Diseases, 2007, 23, 140-147.	1.7	59
423	Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. European Respiratory Journal, 2007, 29, 713-719.	6.7	74
424	Effect of sildenafil on hypoxia-induced changes in pulmonary circulation and right ventricular function. Respiratory Physiology and Neurobiology, 2007, 159, 196-201.	1.6	32
425	Hypoxia-induced pulmonary hypertension: Different impact of iloprost, sildenafil, and nitric oxide. Respiratory Medicine, 2007, 101, 2125-2132.	2.9	27
426	Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs. Respiratory Research, 2007, 8, 4.	3.6	34
427	Comparison of Pharmacokinetics and Vasodilatory Effect of Nebulized and Infused Iloprost in Experimental Pulmonary Hypertension: Rapid Tolerance Development. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2006, 19, 353-363.	1.2	17
428	Favorable Effects of Inhaled Treprostinil in Severe Pulmonary Hypertension. Journal of the American College of Cardiology, 2006, 48, 1672-1681.	2.8	135
429	Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers. Journal of the American College of Cardiology, 2006, 48, 2546-2552.	2.8	498
430	AMBRISENTAN HAS NO CLINICALLY RELEVANT EFFECT ON THE PHARMACOKINETICS OR PHARMACODYNAMICS OF WARFARIN. Chest, 2006, 130, 256S.	0.8	15
431	Inhaled Treprostinil for Treatment of Chronic Pulmonary Arterial Hypertension. Annals of Internal Medicine, 2006, 144, 149.	3.9	33
432	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nature Reviews Drug Discovery, 2006, 5, 689-702.	46.4	471

#	Article	IF	Citations
433	Impact of Mitochondria and NADPH Oxidases on Acute and Sustained Hypoxic Pulmonary Vasoconstriction. American Journal of Respiratory Cell and Molecular Biology, 2006, 34, 505-513.	2.9	90
434	Oxygen sensors in hypoxic pulmonary vasoconstriction. Cardiovascular Research, 2006, 71, 620-629.	3.8	61
435	Hypoxia- and non-hypoxia-related pulmonary hypertension â€" Established and new therapies. Cardiovascular Research, 2006, 72, 30-40.	3.8	49
436	Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling. Circulation, 2006, 113, 286-295.	1.6	208
437	Sildenafil treatment for portopulmonary hypertension. European Respiratory Journal, 2006, 28, 563-567.	6.7	199
438	Sildenafil Improves Dynamic Vascular Function in the Brain: Studies in Patients with Pulmonary Hypertension. Cerebrovascular Diseases, 2006, 21, 194-200.	1.7	54
439	Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19093-19098.	7.1	273
440	Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock. Thrombosis and Haemostasis, 2006, 95, 720-727.	3.4	26
441	Correction: Inhaled Treprostinil for Treatment of Chronic Pulmonary Arterial Hypertension. Annals of Internal Medicine, 2006, 144, 863.	3.9	0
442	Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock. Thrombosis and Haemostasis, 2006, 95, 720-7.	3.4	7
443	Hypoxic pulmonary vasoconstriction--triggered by an increase in reactive oxygen species?. Novartis Foundation Symposium, 2006, 272, 196-208; discussion 208-17.	1.1	7
444	Congenital erythropoietin over-expression causes â€œanti-pulmonary hypertensiveâ€•structural and functional changes in mice, both in normoxia and hypoxia. Thrombosis and Haemostasis, 2005, 94, 630-638.	3.4	31
445	Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB Journal, 2005, 19, 1175-1177.	0.5	158
446	Inhaled Iloprost Reverses Vascular Remodeling in Chronic Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 358-363.	5.6	62
447	Thrombin Impairs Alveolar Fluid Clearance by Promoting Endocytosis of Na+,K+-ATPase. American Journal of Respiratory Cell and Molecular Biology, 2005, 33, 343-354.	2.9	64
448	Oleic Acid Inhibits Alveolar Fluid Reabsorption. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 469-479.	5.6	72
449	Prostanoids and Phosphodiesterase Inhibitors in Experimental Pulmonary Hypertension. Current Topics in Developmental Biology, 2005, 67, 251-284.	2.2	9
450	Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. New England Journal of Medicine, 2005, 353, 2148-2157.	27.0	2,237

#	Article	IF	Citations
451	Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. Respiratory Research, 2005, 6, 128.	3.6	34
452	Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. Respiratory Research, 2005, 6, 76.	3.6	31
453	Detection of reactive oxygen species in isolated, perfused lungs by electron spin resonance spectroscopy. Respiratory Research, 2005, 6, 86.	3.6	32
454	Imatinib for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2005, 353, 1412-1413.	27.0	440
455	Reversal of experimental pulmonary hypertension by PDGF inhibition. Journal of Clinical Investigation, 2005, 115, 2811-2821.	8.2	917
456	Chronic Sildenafil Treatment Inhibits Monocrotaline-induced Pulmonary Hypertension in Rats. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 39-45.	5.6	230
457	Antiremodeling Effects of Iloprost and the Dual-Selective Phosphodiesterase 3/4 Inhibitor Tolafentrine in Chronic Experimental Pulmonary Hypertension. Circulation Research, 2004, 94, 1101-1108.	4.5	97
458	Measurement of exhaled hydrogen peroxide from rabbit lungs. Biological Chemistry, 2004, 385, 259-264.	2.5	9
459	Inhaled iloprost is a potent acute pulmonary vasodilator in HIVâ€related severe pulmonary hypertension. European Respiratory Journal, 2004, 23, 321-326.	6.7	72
460	Prostacyclin and its analogues in the treatment of pulmonary hypertension. , 2004, 102, 139-153.		119
461	Increase in alveolar antioxidant levels in hyperoxic and anoxic ventilated rabbit lungs during ischemia. Free Radical Biology and Medicine, 2004, 36, 78-89.	2.9	14
462	Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species. Free Radical Biology and Medicine, 2004, 36, 1279-1288.	2.9	183
463	Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 43, S68-S72.	2.8	131
464	Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 44, 1488-1496.	2.8	134
465	Basic features of hypoxic pulmonary vasoconstriction in mice. Respiratory Physiology and Neurobiology, 2004, 139, 191-202.	1.6	58
466	Sildenafil Increased Exercise Capacity during Hypoxia at Low Altitudes and at Mount Everest Base Camp. Annals of Internal Medicine, 2004, 141, 169.	3.9	271
467	NO pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. , 2004, , 163-168.		0
468	Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. Journal of the American College of Cardiology, 2003, 42, 158-164.	2.8	359

#	Article	IF	Citations
469	Sildenafil for lung fibrosis and pulmonary hypertension. Lancet, The, 2003, 361, 263.	13.7	0
470	Zardaverine and aerosolised iloprost in a model of acute respiratoryfailure. European Respiratory Journal, 2003, 22, 342-347.	6.7	19
471	Downregulation of hypoxic vasoconstriction by chronic hypoxia in rabbits: effects of nitric oxide. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 284, H931-H938.	3.2	34
472	Sildenafil for Long-Term Treatment of Nonoperable Chronic Thromboembolic Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1139-1141.	5.6	265
473	Effects of Mitochondrial Inhibitors and Uncouplers on Hypoxic Vasoconstriction in Rabbit Lungs. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, 721-732.	2.9	51
474	Pharmacodynamics and Pharmacokinetics of Inhaled Iloprost, Aerosolized by Three Different Devices, in Severe Pulmonary Hypertension. Chest, 2003, 124, 1294-1304.	0.8	124
475	Subthreshold doses of nebulized prostacyclin and rolipram synergistaically protect against lung ischemia-reperfusion. Transplantation, 2003, 75, 814-821.	1.0	7
476	Increased neutrophil mediator release in patients with pulmonary hypertension â€“ suppression by inhaled iloprost. Thrombosis and Haemostasis, 2003, 90, 1141-1149.	3.4	47
477	Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: respondersversusnonresponders. European Respiratory Journal, 2002, 19, 664-671.	6.7	24
478	Pharmacokinetics and Metabolism of Infused versus Inhaled Iloprost in Isolated Rabbit Lungs. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 741-745.	2.5	23
479	Apical, But Not Basolateral, Endotoxin Preincubation Protects Alveolar Epithelial Cells Against Hydrogen Peroxide-Induced Loss of Barrier Function: The Role of Nitric Oxide Synthesis. Journal of Immunology, 2002, 169, 1474-1481.	0.8	16
480	Inhaled Iloprost for Severe Pulmonary Hypertension. New England Journal of Medicine, 2002, 347, 322-329.	27.0	1,626
481	Nocturnal periodic breathing in primary pulmonary hypertension. European Respiratory Journal, 2002, 19, 658-663.	6.7	79
482	Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension. Annals of Internal Medicine, 2002, 136, 515.	3.9	446
483	Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Critical Care Medicine, 2002, 30, 2489-2492.	0.9	69
484	Mediator generation and signaling events in alveolar epithelial cells attacked byS. aureusl±-toxin. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2002, 282, L207-L214.	2.9	57
485	Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet, The, 2002, 360, 895-900.	13.7	720
486	Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension. Journal of the American College of Cardiology, 2001, 38, 1130-1136.	2.8	56

#	Article	IF	Citations
487	NO and reactive oxygen species are involved in biphasic hypoxic vasoconstriction of isolated rabbit lungs. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L638-L645.	2.9	59
488	Conebulization of surfactant and urokinase restores gas exchange in perfused lungs with alveolar fibrin formation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L792-L800.	2.9	17
489	Alveolar epithelial barrier functions in ventilated perfused rabbit lungs. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L896-L904.	2.9	23
490	Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 281, L1361-L1368.	2.9	37
491	Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. European Respiratory Journal, 2001, 17, 14-19.	6.7	100
492	Cellular pathophysiology and therapy of pulmonary hypertension. Translational Research, 2001, 138, 367-377.	2.3	57
493	Coaerosolization of Phosphodiesterase Inhibitors Markedly Enhances the Pulmonary Vasodilatory Response to Inhaled Iloprost in Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1694-1700.	5.6	54
494	Urodilatin, a Natriuretic Peptide Stimulating Particulate Guanylate Cyclase, and the Phosphodiesterase 5 Inhibitor Dipyridamole Attenuate Experimental Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2001, 25, 219-225.	2.9	22
495	Hypoxic vasoconstriction in intact lungs: a role for NADPH oxidase-derived H₂O₂?. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 279, L683-L690.	2.9	87
496	Schwere pulmonale Hypertonie - Vasodilative Therapie in der Lungenstrombahn. Pneumologie, 2000, 54, 160-169.	0.1	0
497	Nitric Oxide (NO)â€“Dependent but Not NO-Independent Guanylate Cyclase Activation Attenuates Hypoxic Vasoconstriction in Rabbit Lungs. American Journal of Respiratory Cell and Molecular Biology, 2000, 23, 222-227.	2.9	24
498	Differential Impact of Ultrasonically Nebulized Versus Tracheal-instilled Surfactant on Ventilation-Perfusion (VË™A/QË™) Mismatch in a Model of Acute Lung Injury. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 152-159.	5.6	29
499	A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. Journal of the American College of Cardiology, 2000, 35, 176-182.	2.8	296
500	Evidence for a role of protein kinase C in hypoxic pulmonary vasoconstriction. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1999, 276, L90-L95.	2.9	43
501	Low-dose Systemic Phosphodiesterase Inhibitors Amplify the Pulmonary Vasodilatory Response to Inhaled Prostacyclin in Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 1500-1506.	5.6	73
502	Prostacyclin Enhances Stretch-induced Surfactant Secretion in Alveolar Epithelial Type II Cells. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 846-851.	5.6	36
503	Inhaled Prostacyclin and Iloprost in Severe Pulmonary Hypertension Secondary to Lung Fibrosis. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 600-607.	5.6	369
504	Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. Intensive Care Medicine, 1998, 24, 631-634.	8.2	59

#	Article	IF	Citations
505	Cyclooxygenase Isoenzyme Localization and mRNA Expression in Rat Lungs. American Journal of Respiratory Cell and Molecular Biology, 1998, 18, 479-488.	2.9	76
506	Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension. Annals of Internal Medicine, 1996, 124, 820.	3.9	347
507	Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis.. American Journal of Respiratory and Critical Care Medicine, 1996, 154, 57-62.	5.6	171
508	Synergism of alveolar endotoxin "priming" and intravascular exotoxin challenge in lung injury.. American Journal of Respiratory and Critical Care Medicine, 1996, 154, 460-468.	5.6	9
509	Endotoxin "priming" potentiates lung vascular abnormalities in response to Escherichia coli hemolysin: an example of synergism between endo- and exotoxin.. Journal of Experimental Medicine, 1994, 180, 1437-1443.	8.5	30
510	Hypoxic Pulmonary Vasoconstriction-Triggered by an Increase in Reactive Oxygen Species?. Novartis Foundation Symposium, 0, , 196-213.	1.1	12
511	Phosphodiesterase-5 Inhibitors in Pulmonary Arterial Hypertension. , 0, , 105-125.		1